| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4029377 | Ophthalmology | 2008 | 9 Pages |
Abstract
Age-related macular degeneration represented a significant economic burden to the U.S. health care system for a single ophthalmic disease entity based on Medicare reimbursed eye-related costs before the availability of photodynamic therapy and anti-vascular endothelial growth factor therapy. Given that direct eye-related costs associated with the treatment of neovascular AMD are estimated at $569 million annually before the availability of therapy for subfoveal lesions, effective therapeutic measures may be associated with substantial cost offsets.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Anne L. MD, PhD, Fei PhD,